Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2015-005419-33 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
This was a randomized, double-blind, double-dummy, active comparatorcontrolled, parallel-group, multi-center study with variable treatment duration in approximately 900 patients with relapsing multiple sclorosis (RMS). The maximal treatment duration in the study for an individual patient was 2.5 years. Eligible patients were randomized to receive either experimental ofatumumab subcutaneous (s.c.) injections every 4 weeks or active comparator teriflunomide orally once daily. The dose regimen for ofatumumab for this study was a loading dose regimen of 20 mg at Day 1, Day 7 and Day 14, followed by a maintenance dose regimen of 20 mg administered every 4 weeks starting at Week 4. In order to blind for the different formulations, double-dummy masking was used, i.e., all patients will take injections (containing either active ofatumumab or placebo) and oral capsules (containing either active teriflunomide or placebo).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OMG 20 mg | Experimental | Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1 ,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide-matching placebo, taken orally once daily |
|
| TER 14 mg | Active Comparator | Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ofatumumab subcutaneous injection | Drug | Ofatumumab 20 mg prefilled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter |
|
| Measure | Description | Time Frame |
|---|---|---|
| Annualized Relapse Rate (ARR) | ARR was the number of confirmed relapses in a year, calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of time in study. A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system). Comparisons were made to the previous rating (the last EDSS rating that did not occur during a relapse). | Baseline up to 2.5 years |
| Measure | Description | Time Frame |
|---|---|---|
| 3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Pooled Data | A 3-month confirmed disability worsening (3mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 3 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35233-0271 | United States | ||
| Novartis Investigative Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39018512 | Derived | Williams MJ, Amezcua L, Cohan SL, Cohen JA, Delgado SR, Hua LH, Lucassen EB, Piccolo RS, Koulouris CR, Stankiewicz J. Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses. Neurology. 2024 Aug 13;103(3):e209610. doi: 10.1212/WNL.0000000000209610. Epub 2024 Jul 17. | |
| 37606897 |
Not provided
Not provided
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Not provided
Not provided
Not provided
Not provided
A total of 1280 patients were screened, of whom 955 patients were randomized into the study.
It was pre-specified in the protocol to combine the data from this study with study NCT02792218 (COMB157G2301) for some outcome measures. Please refer to NCT02792218 for Participant Flow information for participants from other study.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | OMB 20 mg | Ofatumumab 20 mg s.c. injections on Days 1, 7, 14, Week 4 and every 4 weeks thereafter (+ teriflunomide-matching placebo capsule orally once daily) |
| FG001 | TER 14 mg |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Aug 6, 2018 | Sep 18, 2020 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Teriflunomide-matching placebo capsules | Drug | Placebo capsule, matching in appearance to teriflunomide, taken orally once daily |
|
| Teriflunomide capsule | Drug | Teriflunomide 14 mg oral capsule taken once daily |
|
| Matching placebo of ofatumumab subcutaneous injections | Drug | Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter |
|
| Baseline, every 3 months up to 2.5 years |
| 3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Study COMB157G2302 | A 3-month confirmed disability worsening (3mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 3 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline, every 3 months up to 2.5 years |
| 6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Pooled Data | A 6-month confirmed disability worsening (6mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 6 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline, every 3 months up to 2.5 years |
| 6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Study COMB157G2302 | A 6-month confirmed disability worsening (6mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 6 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline, every 3 months up to 2.5 years |
| 6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Pooled Data | A 6-month confirmed disability improvement (6mCDI) was defined as a decrease from baseline EDSS sustained for at least 6 months. For patients with a baseline EDSS of 0 to 1.5, no disability improvement was possible based on the protocol definition of an improvement; for patients with a baseline EDSS of ≥2 to 6 or ≥6.5 to 9.5, the criterion for disability improvement was a decrease in EDSS of ≤1 or ≤0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline, every 3 months up to 2.5 years |
| 6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Study COMB157G2302 | A 6-month confirmed disability improvement (6mCDI) was defined as a decrease from baseline EDSS sustained for at least 6 months. For patients with a baseline EDSS of 0 to 1.5, no disability improvement was possible based on the protocol definition of an improvement; for patients with a baseline EDSS of ≥2 to 6 or ≥6.5 to 9.5, the criterion for disability improvement was a decrease in EDSS of ≤1 or ≤0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline, every 3 months up to 2.5 years |
| Number of Gadolinium-enhancing T1 Lesions Per MRI Scan | Total number of Gd-enhancing T1 lesions across all scans per patient adjusted for different number of scans due to variable follow-up time in study. | Baseline, yearly up to 2.5 years |
| Number of New or Enlarging T2 Lesions on MRI Per Year (Annualized Lesion Rate) | Number of new/enlarging T2 lesions on last available MRI scan compared to baseline adjusted for different time of scans versus baseline due to variable follow up time in study | Baseline, yearly up to 2.5 years |
| Neurofilament Light Chain (NfL) Concentration in Serum | The NfL concentration (geometric mean concentration) was estimated by treatment and time point with using a repeated measures model on the basis of all evaluable log-transformed NfL values. | Month 3, 12 and 24 |
| Annualized Rate of Brain Volume Loss Based on Assessments of Percent Brain Volume Change From Baseline | Percent change from baseline in brain volume loss (BVL) on all MRI scans adjusted for different time of scan versus baseline due to variable follow up time in study | Baseline, Months 12 and 24 |
| Participants With Confirmed Relapse | A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system). | Baseline up to 2.5 years |
| Annualized Relapse Rate (ARR) >8 Weeks After Onset of Treatment | ARR was the number of confirmed relapses in a year, calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of time in study. A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system). Comparisons were made to the previous rating (the last EDSS rating that did not occur during a relapse). | Baseline up to 2.5 years |
| 3-month Confirmed Disability Worsening (3mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data | A 3-month confirmed disability worsening (3mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 3 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline up to 2.5 years |
| 6-month Confirmed Disability Worsening (6mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data | A 6-month confirmed disability worsening (6mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 6 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline up to 2.5 years |
| 6-month Confirmed Cognitive Decline on Symbol Digit Modalities Test (SDMT) - Pooled Data | A 6-month confirmed cognitive decline was defined as a decrease from baseline of at least 4 points in SDMT score sustained for at least 6 months. Processing speed was measured by the Symbol Digit Modalities Test (SDMT) score. SDMT measures the time to pair abstract symbols with specific numbers. The test requires visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items in 90 seconds. (max=110, min=0). Higher scores indicate improvement. Lower scores indicate worsening. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint | Baseline, every 6 months up to 2.5 years |
| 6-month Confirmed Disability Worsening (6mCDW) or 6-month Confirmed Cognitive Decline (6mCCD) - Pooled Data | A 6-month confirmed disability worsening (6mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 6 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. A 6-month confirmed cognitive decline (6mCCD) was defined as a 4-point worsening on Symbol Digit Modalities Test (SDMT) sustained for at least 6 months. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline up to 2.5 years |
| Change in Cognitive Performance Measured by the Symbol Digit Modalities Test (SDMT) - Pooled Data | Processing speed is being measured by the Symbol Digit Modalities Test (SDMT) score. SDMT measures the time to pair abstract symbols with specific numbers. The test requires visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items in 90 seconds. (max=110, min=0). Higher scores indicate improvement. Lower scores indicate worsening. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline up to 2.5 years |
| 6-month Confirmed Worsening of at Least 20% in the Timed 25-Foot Walk (T25FW) - Pooled Data | The patient is directed to walk 25 feet quickly and safely as possible from one marked end to the other. The time is calculated from the initiation of the patient instructed to begin, until the patient has reached the 25-foot mark. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline, every 3 months up to 2.5 years |
| 6-month Confirmed Worsening of at Least 20% in the 9-Hole Peg Test (9HPT) - Pooled Data | 9-Hole Peg Test is a test of upper limb function. Participants place 9 pegs on pegboard and remove pegs and this is timed for each hand. Time recorded in seconds. Longer time indicates poorer upper limb function. 20% improvement is defined as 20% shorter time in seconds. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline, every 6 months up to 2.5 years |
| 6-month Confirmed Disability Improvement (6mCDI) Sustained Until End of Study (EOS) as Measured by EDSS - Pooled Data | A 6-month confirmed disability improvement (6mCDI) sustained until EOS was defined as a decrease from baseline EDSS sustained until EOS. For patients with a baseline EDSS of 0 to 1.5, no disability improvement was possible based on the protocol definition of an improvement; for patients with a baseline EDSS of ≥2 to 6 or ≥6.5 to 9.5, the criterion for disability improvement was a decrease in EDSS of ≤1 or ≤0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Baseline, every 3 months up to 2.5 years |
| Number of New or Enlarging T2 Lesions on MRI Per Year From Month 12 Until End of Study (EOS) | Number of new/enlarging T2 lesions on the last available MRI scan compared to Month 12 adjusted for different time of scans versus Month 12 due to variable follow up time in study. | Month 12 up to 2.5 years |
| Percent Change in T2 Lesion Volume Relative to Baseline | Percent change from baseline in total T2 lesion volume | Baseline, Month 12, Month 24 |
| No Evidence of Disease Activity (NEDA-4) | NEDA-4 was defined as no 3-month confirmed disability worsening, no confirmed MS relapse, no new or enlarging T2 lesions compared to baseline, and the annualized rate of brain atrophy >-0.04%. | Baseline, Month 12, Month 24 |
| Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score Change From Baseline | MSIS-29 is a 29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life. | Baseline, every 6 months up to 2.5 years |
| Multiple Sclerosis Impact Scale (MSIS-29) Psychological Impact Score Change From Baseline | MSIS-29 is a 29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life. | Baseline, every 6 months up to 2.5 years |
| Annualized Relapse Rates (ARR) by NfL High-low Subgroups - Pooled Data | ARR was the number of confirmed relapses in a year, calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of time in study. A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system). | Baseline up to 2.5 years |
| Number of New or Enlarging T2 Lesions Per Year by NfL High-low Subgroups - Pooled Data | Number of new or enlarging T2 lesions on MRI per year (annualized lesion rate). | Baseline, yearly up to 2.5 years |
| Brain Volume Loss by NfL High-low Subgroups - Pooled Data | Percent change from baseline in brain volume loss (BVL) on all MRI scans adjusted for different time of scan versus baseline due to variable follow up time in study. | Baseline, Months 12 and 24 |
| Pharmacokinetic (PK) Concentrations of Ofatumumab | Summary statistics of pharmacokinetic (PK) concentrations from trough samples collected within a 7-day window prior or at day of dosing. | Baseline, Weeks 4, 12, 24, 48, 96 |
| Cullman |
| Alabama |
| 35058 |
| United States |
| Novartis Investigative Site | Tucson | Arizona | 85704 | United States |
| Novartis Investigative Site | Aurora | Colorado | 80045 | United States |
| Novartis Investigative Site | Basalt | Colorado | 81621 | United States |
| Novartis Investigative Site | Boulder | Colorado | 80301 | United States |
| Novartis Investigative Site | Centennial | Colorado | 80112 | United States |
| Novartis Investigative Site | Colorado Springs | Colorado | 80907 | United States |
| Novartis Investigative Site | Denver | Colorado | 80210 | United States |
| Novartis Investigative Site | Fort Collins | Colorado | 80528 | United States |
| Novartis Investigative Site | Fort Collins | Colorado | 907-280528 | United States |
| Novartis Investigative Site | Fairfield | Connecticut | 06824 | United States |
| Novartis Investigative Site | Newark | Delaware | 19713 | United States |
| Novartis Investigative Site | Bradenton | Florida | 34205 | United States |
| Novartis Investigative Site | Gainesville | Florida | 32611 | United States |
| Novartis Investigative Site | Maitland | Florida | 32751 | United States |
| Novartis Investigative Site | Ocala | Florida | 34471 | United States |
| Novartis Investigative Site | Oldsmar | Florida | 34677 | United States |
| Novartis Investigative Site | Ormond Beach | Florida | 32174 | United States |
| Novartis Investigative Site | Palm Coast | Florida | 32164 | United States |
| Novartis Investigative Site | Sarasota | Florida | 34243 | United States |
| Novartis Investigative Site | St. Petersburg | Florida | 33713 | United States |
| Novartis Investigative Site | Tallahassee | Florida | 32312 | United States |
| Novartis Investigative Site | Tampa | Florida | 33603 | United States |
| Novartis Investigative Site | Tampa | Florida | 33609 | United States |
| Novartis Investigative Site | Tampa | Florida | 33612 | United States |
| Novartis Investigative Site | Suwanee | Georgia | 30024 | United States |
| Novartis Investigative Site | Anderson | Indiana | 46011 | United States |
| Novartis Investigative Site | Indianapolis | Indiana | 46256 | United States |
| Novartis Investigative Site | Wellesley | Massachusetts | 02481 | United States |
| Novartis Investigative Site | Detroit | Michigan | 48202 | United States |
| Novartis Investigative Site | Golden Valley | Minnesota | 55422 | United States |
| Novartis Investigative Site | Billings | Montana | 59101 | United States |
| Novartis Investigative Site | Great Falls | Montana | 59405 | United States |
| Novartis Investigative Site | Albuquerque | New Mexico | 87131-0001 | United States |
| Novartis Investigative Site | Asheville | North Carolina | 28806 | United States |
| Novartis Investigative Site | Charlotte | North Carolina | 28202 | United States |
| Novartis Investigative Site | Greensboro | North Carolina | 27405 | United States |
| Novartis Investigative Site | Akron | Ohio | 44320 | United States |
| Novartis Investigative Site | Columbus | Ohio | 43214 | United States |
| Novartis Investigative Site | Columbus | Ohio | 43221 | United States |
| Novartis Investigative Site | Westerville | Ohio | 43081 | United States |
| Novartis Investigative Site | Portland | Oregon | 97225 | United States |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15212 | United States |
| Novartis Investigative Site | Willow Grove | Pennsylvania | 19090 | United States |
| Novartis Investigative Site | Greer | South Carolina | 29650 | United States |
| Novartis Investigative Site | Cordova | Tennessee | 38018 | United States |
| Novartis Investigative Site | Knoxville | Tennessee | 37922 | United States |
| Novartis Investigative Site | Nashville | Tennessee | 37205 | United States |
| Novartis Investigative Site | Greenville | Texas | 75401 | United States |
| Novartis Investigative Site | Lubbock | Texas | 79410 | United States |
| Novartis Investigative Site | Sherman | Texas | 75092 | United States |
| Novartis Investigative Site | Orem | Utah | 84058 | United States |
| Novartis Investigative Site | Salt Lake City | Utah | 84103 | United States |
| Novartis Investigative Site | Salt Lake City | Utah | 84132 | United States |
| Novartis Investigative Site | Kirkland | Washington | 98034 | United States |
| Novartis Investigative Site | Seattle | Washington | 98122 | United States |
| Novartis Investigative Site | Tacoma | Washington | 98405 | United States |
| Novartis Investigative Site | Waukesha | Wisconsin | 53188 | United States |
| Novartis Investigative Site | CABA | Buenos Aires | C1428AQK | Argentina |
| Novartis Investigative Site | Rosario | Santa Fe Province | S2000DSW | Argentina |
| Novartis Investigative Site | San Miguel de Tucumán | 4000 | Argentina |
| Novartis Investigative Site | Liverpool | New South Wales | 2170 | Australia |
| Novartis Investigative Site | Vienna | 1010 | Austria |
| Novartis Investigative Site | Vienna | 1090 | Austria |
| Novartis Investigative Site | Edegem | Antwerpen | 2650 | Belgium |
| Novartis Investigative Site | Aalst | 9300 | Belgium |
| Novartis Investigative Site | Brussels | 1200 | Belgium |
| Novartis Investigative Site | Ghent | 9000 | Belgium |
| Novartis Investigative Site | Sofia | 1113 | Bulgaria |
| Novartis Investigative Site | Sofia | 1413 | Bulgaria |
| Novartis Investigative Site | London | Ontario | N6A 5A5 | Canada |
| Novartis Investigative Site | Ottawa | Ontario | K1H 8L6 | Canada |
| Novartis Investigative Site | Toronto | Ontario | M4N 3M5 | Canada |
| Novartis Investigative Site | Greenfield Park | Quebec | J4V 2J2 | Canada |
| Novartis Investigative Site | Osijek | 31000 | Croatia |
| Novartis Investigative Site | Zagreb | 10000 | Croatia |
| Novartis Investigative Site | Brno | Czech Republic | 656 91 | Czechia |
| Novartis Investigative Site | Havířov | Czech Republic | 736 01 | Czechia |
| Novartis Investigative Site | Teplice | Czech Republic | 415 01 | Czechia |
| Novartis Investigative Site | Ostrava-Poruba | 708 52 | Czechia |
| Novartis Investigative Site | Prague | 100 34 | Czechia |
| Novartis Investigative Site | Tampere | 33100 | Finland |
| Novartis Investigative Site | Turku | 20520 | Finland |
| Novartis Investigative Site | Nice | Cedex1 | 06001 | France |
| Novartis Investigative Site | Bordeaux | 33076 | France |
| Novartis Investigative Site | Clermont-Ferrand | 63000 | France |
| Novartis Investigative Site | Montpellier | 34295 | France |
| Novartis Investigative Site | Paris | 75651 | France |
| Novartis Investigative Site | Rennes | 35033 | France |
| Novartis Investigative Site | Strasbourg | 67098 | France |
| Novartis Investigative Site | Bochum | 44791 | Germany |
| Novartis Investigative Site | Cologne | 50935 | Germany |
| Novartis Investigative Site | Dresden | 01307 | Germany |
| Novartis Investigative Site | Essen | 45147 | Germany |
| Novartis Investigative Site | Hamburg | 22179 | Germany |
| Novartis Investigative Site | Hanover | 30625 | Germany |
| Novartis Investigative Site | Heidelberg | 69120 | Germany |
| Novartis Investigative Site | Homburg | 66421 | Germany |
| Novartis Investigative Site | Leipzig | 04103 | Germany |
| Novartis Investigative Site | Leipzig | 04107 | Germany |
| Novartis Investigative Site | Minden | 32429 | Germany |
| Novartis Investigative Site | Siegen | 57076 | Germany |
| Novartis Investigative Site | Ulm | 89081 | Germany |
| Novartis Investigative Site | Unterhaching | 82008 | Germany |
| Novartis Investigative Site | Budapest | HUN | 1204 | Hungary |
| Novartis Investigative Site | Esztergom | HUN | 2500 | Hungary |
| Novartis Investigative Site | Hyderabad | Andhra Pradesh | 500018 | India |
| Novartis Investigative Site | Mumbai | Maharashtra | 400008 | India |
| Novartis Investigative Site | Mumbai | Maharashtra | 400012 | India |
| Novartis Investigative Site | Pune | Maharashtra | 411004 | India |
| Novartis Investigative Site | New Delhi | National Capital Territory of Delhi | 110 060 | India |
| Novartis Investigative Site | Ludhiana | Punjab | 141008 | India |
| Novartis Investigative Site | Mumbai | 400016 | India |
| Novartis Investigative Site | Padova | PD | 35128 | Italy |
| Novartis Investigative Site | Roma | RM | 00133 | Italy |
| Novartis Investigative Site | Genova | 16132 | Italy |
| Novartis Investigative Site | Milan | 20133 | Italy |
| Novartis Investigative Site | Naples | 80138 | Italy |
| Novartis Investigative Site | Rome | 00178 | Italy |
| Novartis Investigative Site | Riga | LV | LV-1005 | Latvia |
| Novartis Investigative Site | Riga | LV 1002 | Latvia |
| Novartis Investigative Site | Riga | LV-1038 | Latvia |
| Novartis Investigative Site | Kaunas | LTU | LT 50161 | Lithuania |
| Novartis Investigative Site | Vilnius | LT-08661 | Lithuania |
| Novartis Investigative Site | Chihuahua City | 31238 | Mexico |
| Novartis Investigative Site | Drammen | 1086 | Norway |
| Novartis Investigative Site | Lima Cercado | Lima region | 01 | Peru |
| Novartis Investigative Site | San Isidro | Lima region | 27 | Peru |
| Novartis Investigative Site | Lima | LIMA 13 | Peru |
| Novartis Investigative Site | Głogów | 36-060 | Poland |
| Novartis Investigative Site | Rzeszów | 35 055 | Poland |
| Novartis Investigative Site | Warsaw | 02 957 | Poland |
| Novartis Investigative Site | Wroclaw | 51-685 | Poland |
| Novartis Investigative Site | Zabrze | 41-800 | Poland |
| Novartis Investigative Site | Matosinhos Municipality | Porto District | 4454509 | Portugal |
| Novartis Investigative Site | Amadora | 2720-276 | Portugal |
| Novartis Investigative Site | Braga | 4710243 | Portugal |
| Novartis Investigative Site | Coimbra | 3000-075 | Portugal |
| Novartis Investigative Site | Lisbon | 1169-050 | Portugal |
| Novartis Investigative Site | Lisbon | 1500 650 | Portugal |
| Novartis Investigative Site | Lisbon | 1600190 | Portugal |
| Novartis Investigative Site | Loures | 2674514 | Portugal |
| Novartis Investigative Site | Porto | 4000001 | Portugal |
| Novartis Investigative Site | Santa Maria da Feira | 4520 211 | Portugal |
| Novartis Investigative Site | Kazan' | 420021 | Russia |
| Novartis Investigative Site | Krasnoyarsk | 660049 | Russia |
| Novartis Investigative Site | Moscow | 127015 | Russia |
| Novartis Investigative Site | Nizhny Novgorod | 603137 | Russia |
| Novartis Investigative Site | Novosibirsk | 630087 | Russia |
| Novartis Investigative Site | Saint Petersburg | 197022 | Russia |
| Novartis Investigative Site | Saint Petersburg | 197110 | Russia |
| Novartis Investigative Site | Saint Petersburg | 197376 | Russia |
| Novartis Investigative Site | Yekaterinburg | 620109 | Russia |
| Novartis Investigative Site | Bratislava | 813 69 | Slovakia |
| Novartis Investigative Site | Martin | 036 59 | Slovakia |
| Novartis Investigative Site | Ružomberok | 03426 | Slovakia |
| Novartis Investigative Site | Pretoria | 0041 | South Africa |
| Novartis Investigative Site | Rosebank | 2196 | South Africa |
| Novartis Investigative Site | Málaga | Andalusia | 29010 | Spain |
| Novartis Investigative Site | Seville | Andalusia | 41017 | Spain |
| Novartis Investigative Site | Pozuelo de Alarcón | Madrid | 28223 | Spain |
| Novartis Investigative Site | Barakaldo | Vizcaya | 48903 | Spain |
| Novartis Investigative Site | Donostia / San Sebastian | 20014 | Spain |
| Novartis Investigative Site | Madrid | 28006 | Spain |
| Novartis Investigative Site | Madrid | 28034 | Spain |
| Novartis Investigative Site | Madrid | 28040 | Spain |
| Novartis Investigative Site | Madrid | 28222 | Spain |
| Novartis Investigative Site | Lugano | 6900 | Switzerland |
| Novartis Investigative Site | Tainan | 70403 | Taiwan |
| Novartis Investigative Site | Haseki / Istanbul | 34096 | Turkey (Türkiye) |
| Novartis Investigative Site | Izmir | 35340 | Turkey (Türkiye) |
| Novartis Investigative Site | Mersin | 33079 | Turkey (Türkiye) |
| Novartis Investigative Site | Trabzon | 61080 | Turkey (Türkiye) |
| Novartis Investigative Site | Luton | Beds | LU4 0DZ | United Kingdom |
| Novartis Investigative Site | Sheffield | South Yorkshire | S10 2JF | United Kingdom |
| Novartis Investigative Site | London | SE5 9RS | United Kingdom |
| Novartis Investigative Site | London | SW17 0QT | United Kingdom |
| Bhan V, Clift F, Baharnoori M, Thomas K, Patel BP, Blanchette F, Adlard N, Vudumula U, Gudala K, Dutta N, Grima D, Mouallif S, Farhane F. Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. J Comp Eff Res. 2023 Sep;12(9):e220175. doi: 10.57264/cer-2022-0175. Epub 2023 Aug 22. |
| 35266417 | Derived | Gartner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Haring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, Kappos L. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Mult Scler. 2022 Sep;28(10):1562-1575. doi: 10.1177/13524585221078825. Epub 2022 Mar 10. |
| 32757523 | Derived | Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Haring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. |
Teriflunomide 14 mg capsule orally once daily (+ ofatumumab-matching placebo injections on Days 1, 7, 14, Week 4 and every 4 weeks thereafter)
| COMPLETED |
|
| NOT COMPLETED |
|
|
It was pre-specified in the protocol to combine the data from this study with study NCT02792218 (COMB157G2301) for some outcome measures. Please refer to NCT02792218 for Baseline information for participants from other study.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | OMB 20 mg | Ofatumumab 20 mg s.c. injections on Days 1, 7, 14, Week 4 and every 4 weeks thereafter (+ teriflunomide-matching placebo capsule orally once daily) |
| BG001 | TER 14 mg | Teriflunomide 14 mg capsule orally once daily (+ ofatumumab-matching placebo injections on Days 1, 7, 14, Week 4 and every 4 weeks thereafter) |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
| ||||||||||||||||
| Number of relapses in the past 12 months prior to screening | Reported numbers are from investigator records | Mean | Standard Deviation | Number of relapses |
| ||||||||||||||
| Expanded Disability Status Scale (EDSS) | The EDSS uses an ordinal scale to assess neurologic impairment in MS based on a neurological examination. Scores in each of 7 functional systems (Visual, Brain Stem, Pyramidal, Cerebellar,Sensory, Bowel & Bladder, and Cerebral) and an ambulation score were combined to determine the EDSS steps, ranging from 0 (normal) to 10 (death due to MS). | Participants with data that met requirements for analysis were included | Mean | Standard Deviation | Score on a scale |
| |||||||||||||
| Number of gadolinium-enhancing T1 lesions | Magnetic Resonance Imaging (MRI) scans of the brain were were read by the central MRI reading center. The central reading center was blinded with no access to information on treatment assignments | Participants with data that met requirements for analysis were included | Mean | Standard Deviation | T1 lesions |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Annualized Relapse Rate (ARR) | ARR was the number of confirmed relapses in a year, calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of time in study. A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system). Comparisons were made to the previous rating (the last EDSS rating that did not occur during a relapse). | Full analysis set | Posted | Mean | 95% Confidence Interval | number of relapses in a year | Baseline up to 2.5 years |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Pooled Data | A 3-month confirmed disability worsening (3mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 3 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set from combined studies | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, every 3 months up to 2.5 years |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Study COMB157G2302 | A 3-month confirmed disability worsening (3mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 3 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, every 3 months up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Pooled Data | A 6-month confirmed disability worsening (6mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 6 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set from combined studies | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, every 3 months up to 2.5 years |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Study COMB157G2302 | A 6-month confirmed disability worsening (6mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 6 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, every 3 months up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Pooled Data | A 6-month confirmed disability improvement (6mCDI) was defined as a decrease from baseline EDSS sustained for at least 6 months. For patients with a baseline EDSS of 0 to 1.5, no disability improvement was possible based on the protocol definition of an improvement; for patients with a baseline EDSS of ≥2 to 6 or ≥6.5 to 9.5, the criterion for disability improvement was a decrease in EDSS of ≤1 or ≤0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set from combined studies | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, every 3 months up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Study COMB157G2302 | A 6-month confirmed disability improvement (6mCDI) was defined as a decrease from baseline EDSS sustained for at least 6 months. For patients with a baseline EDSS of 0 to 1.5, no disability improvement was possible based on the protocol definition of an improvement; for patients with a baseline EDSS of ≥2 to 6 or ≥6.5 to 9.5, the criterion for disability improvement was a decrease in EDSS of ≤1 or ≤0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, every 3 months up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Gadolinium-enhancing T1 Lesions Per MRI Scan | Total number of Gd-enhancing T1 lesions across all scans per patient adjusted for different number of scans due to variable follow-up time in study. | Full analysis set | Posted | Mean | 95% Confidence Interval | lesions per scan | Baseline, yearly up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of New or Enlarging T2 Lesions on MRI Per Year (Annualized Lesion Rate) | Number of new/enlarging T2 lesions on last available MRI scan compared to baseline adjusted for different time of scans versus baseline due to variable follow up time in study | Full analysis set | Posted | Mean | 95% Confidence Interval | T2 lesions per year | Baseline, yearly up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Neurofilament Light Chain (NfL) Concentration in Serum | The NfL concentration (geometric mean concentration) was estimated by treatment and time point with using a repeated measures model on the basis of all evaluable log-transformed NfL values. | Full analysis set | Posted | Geometric Mean | 95% Confidence Interval | pg/mL | Month 3, 12 and 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Annualized Rate of Brain Volume Loss Based on Assessments of Percent Brain Volume Change From Baseline | Percent change from baseline in brain volume loss (BVL) on all MRI scans adjusted for different time of scan versus baseline due to variable follow up time in study | Full analysis set | Posted | Mean | 95% Confidence Interval | percentage of brain volume loss | Baseline, Months 12 and 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Participants With Confirmed Relapse | A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system). | Full analysis set | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Annualized Relapse Rate (ARR) >8 Weeks After Onset of Treatment | ARR was the number of confirmed relapses in a year, calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of time in study. A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system). Comparisons were made to the previous rating (the last EDSS rating that did not occur during a relapse). | Full analysis set | Posted | Mean | 95% Confidence Interval | number of relapses in a year | Baseline up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 3-month Confirmed Disability Worsening (3mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data | A 3-month confirmed disability worsening (3mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 3 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set from combined studies. | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline up to 2.5 years |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 6-month Confirmed Disability Worsening (6mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data | A 6-month confirmed disability worsening (6mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 6 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set from combined studies. | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline up to 2.5 years |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 6-month Confirmed Cognitive Decline on Symbol Digit Modalities Test (SDMT) - Pooled Data | A 6-month confirmed cognitive decline was defined as a decrease from baseline of at least 4 points in SDMT score sustained for at least 6 months. Processing speed was measured by the Symbol Digit Modalities Test (SDMT) score. SDMT measures the time to pair abstract symbols with specific numbers. The test requires visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items in 90 seconds. (max=110, min=0). Higher scores indicate improvement. Lower scores indicate worsening. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint | Full analysis set from combined studies | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, every 6 months up to 2.5 years |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 6-month Confirmed Disability Worsening (6mCDW) or 6-month Confirmed Cognitive Decline (6mCCD) - Pooled Data | A 6-month confirmed disability worsening (6mCDW) was defined as an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 6 months. For patients with a baseline EDSS of 0, the criterion for disability worsening was an increase in EDSS of ≥1.5, for patients with a baseline EDSS of 1 to 5 or ≥5.5, the criterion for disability worsening was an increase in EDSS of ≥1 or ≥0.5, respectively. A 6-month confirmed cognitive decline (6mCCD) was defined as a 4-point worsening on Symbol Digit Modalities Test (SDMT) sustained for at least 6 months. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set from combined studies. | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline up to 2.5 years |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change in Cognitive Performance Measured by the Symbol Digit Modalities Test (SDMT) - Pooled Data | Processing speed is being measured by the Symbol Digit Modalities Test (SDMT) score. SDMT measures the time to pair abstract symbols with specific numbers. The test requires visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items in 90 seconds. (max=110, min=0). Higher scores indicate improvement. Lower scores indicate worsening. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set from combined studies. | Posted | Mean | 95% Confidence Interval | scores | Baseline up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 6-month Confirmed Worsening of at Least 20% in the Timed 25-Foot Walk (T25FW) - Pooled Data | The patient is directed to walk 25 feet quickly and safely as possible from one marked end to the other. The time is calculated from the initiation of the patient instructed to begin, until the patient has reached the 25-foot mark. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set from combined studies. | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, every 3 months up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 6-month Confirmed Worsening of at Least 20% in the 9-Hole Peg Test (9HPT) - Pooled Data | 9-Hole Peg Test is a test of upper limb function. Participants place 9 pegs on pegboard and remove pegs and this is timed for each hand. Time recorded in seconds. Longer time indicates poorer upper limb function. 20% improvement is defined as 20% shorter time in seconds. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set from combined studies. | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, every 6 months up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | 6-month Confirmed Disability Improvement (6mCDI) Sustained Until End of Study (EOS) as Measured by EDSS - Pooled Data | A 6-month confirmed disability improvement (6mCDI) sustained until EOS was defined as a decrease from baseline EDSS sustained until EOS. For patients with a baseline EDSS of 0 to 1.5, no disability improvement was possible based on the protocol definition of an improvement; for patients with a baseline EDSS of ≥2 to 6 or ≥6.5 to 9.5, the criterion for disability improvement was a decrease in EDSS of ≤1 or ≤0.5, respectively. This study was not powered for the analysis of this endpoint individually. It was pre-specified in the study protocol to combine the data from this study with study COMB157G2301 to address this endpoint. | Full analysis set from combined studies. | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, every 3 months up to 2.5 years |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of New or Enlarging T2 Lesions on MRI Per Year From Month 12 Until End of Study (EOS) | Number of new/enlarging T2 lesions on the last available MRI scan compared to Month 12 adjusted for different time of scans versus Month 12 due to variable follow up time in study. | Full analysis set | Posted | Mean | 95% Confidence Interval | T2 lesions per year | Month 12 up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percent Change in T2 Lesion Volume Relative to Baseline | Percent change from baseline in total T2 lesion volume | Full analysis set | Posted | Mean | Standard Deviation | percentage change in lesion volume | Baseline, Month 12, Month 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | No Evidence of Disease Activity (NEDA-4) | NEDA-4 was defined as no 3-month confirmed disability worsening, no confirmed MS relapse, no new or enlarging T2 lesions compared to baseline, and the annualized rate of brain atrophy >-0.04%. | Full analysis set. | Posted | Number | 95% Confidence Interval | percentage of participants | Baseline, Month 12, Month 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score Change From Baseline | MSIS-29 is a 29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life. | Full analysis set | Posted | Mean | Standard Error | scores on a scale | Baseline, every 6 months up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Multiple Sclerosis Impact Scale (MSIS-29) Psychological Impact Score Change From Baseline | MSIS-29 is a 29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life. | Full analysis set | Posted | Mean | Standard Error | scores on a scale | Baseline, every 6 months up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Annualized Relapse Rates (ARR) by NfL High-low Subgroups - Pooled Data | ARR was the number of confirmed relapses in a year, calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of time in study. A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system). | Supportive sub-group analysis based on estimations from pooled data from this study and study COMB157G2301. | Posted | Mean | 95% Confidence Interval | number of relapses in a year | Baseline up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of New or Enlarging T2 Lesions Per Year by NfL High-low Subgroups - Pooled Data | Number of new or enlarging T2 lesions on MRI per year (annualized lesion rate). | Supportive sub-group analysis based on estimations from pooled data from this study and study COMB157G2301. | Posted | Mean | 95% Confidence Interval | T2 lesions per year | Baseline, yearly up to 2.5 years |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Brain Volume Loss by NfL High-low Subgroups - Pooled Data | Percent change from baseline in brain volume loss (BVL) on all MRI scans adjusted for different time of scan versus baseline due to variable follow up time in study. | Supportive sub-group analysis based on estimations from pooled data from this study and study COMB157G2301. | Posted | Mean | 95% Confidence Interval | percentage of brain volume loss | Baseline, Months 12 and 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Pharmacokinetic (PK) Concentrations of Ofatumumab | Summary statistics of pharmacokinetic (PK) concentrations from trough samples collected within a 7-day window prior or at day of dosing. | Full analysis set | Posted | Mean | Standard Deviation | ug/mL | Baseline, Weeks 4, 12, 24, 48, 96 |
|
|
Adverse events were reported from first dose of study treatment until last administration of study treatment plus 100 days post treatment, up to maximum duration of approximately 2.7 years
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | OMB 20mg | Ofatumumab 20 mg s.c. injections on Days 1, 7, 14, Week 4 and every 4 weeks thereafter (+ teriflunomide-matching placebo capsule orally once daily) | 0 | 481 | 42 | 481 | 348 | 481 |
| EG001 | TER 14mg | Teriflunomide 14 mg capsule orally once daily (+ ofatumumab-matching placebo injections on Days 1, 7, 14, Week 4 and every 4 weeks thereafter) | 1 | 474 | 37 | 474 | 322 | 474 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Bundle branch block bilateral | Cardiac disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Coronary artery disease | Cardiac disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Nodal arrhythmia | Cardiac disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Diplopia | Eye disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Enteritis | Gastrointestinal disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Intestinal obstruction | Gastrointestinal disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Pancreatitis acute | Gastrointestinal disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Umbilical hernia | Gastrointestinal disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Drug withdrawal syndrome | General disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Non-cardiac chest pain | General disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Cholecystitis | Hepatobiliary disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Hepatic failure | Hepatobiliary disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Appendicitis | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Cystitis | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Lower respiratory tract infection | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Osteomyelitis | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Paronychia | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Peritonitis | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Postoperative abscess | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Respiratory tract infection viral | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Urosepsis | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Viral infection | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Bone contusion | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Concussion | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Craniocerebral injury | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Femoral neck fracture | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Head injury | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Humerus fracture | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Incisional hernia | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Joint dislocation | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Ligament sprain | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Post procedural haematoma | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Post procedural inflammation | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Radius fracture | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Rib fracture | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Road traffic accident | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Tendon injury | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Upper limb fracture | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Intervertebral disc compression | Musculoskeletal and connective tissue disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Pathological fracture | Musculoskeletal and connective tissue disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Spondylitis | Musculoskeletal and connective tissue disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (22.0) | Systematic Assessment |
| |
| Fibroadenoma of breast | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (22.0) | Systematic Assessment |
| |
| Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (22.0) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Lumbar radiculopathy | Nervous system disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Multiple sclerosis | Nervous system disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Multiple sclerosis relapse | Nervous system disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Myelopathy | Nervous system disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Quadriplegia | Nervous system disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Trigeminal neuralgia | Nervous system disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Major depression | Psychiatric disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Suicidal ideation | Psychiatric disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Suicide attempt | Psychiatric disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Urinary retention | Renal and urinary disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Benign prostatic hyperplasia | Reproductive system and breast disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Testicular infarction | Reproductive system and breast disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Uterine haemorrhage | Reproductive system and breast disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Uterine polyp | Reproductive system and breast disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Uterovaginal prolapse | Reproductive system and breast disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Pulmonary sarcoidosis | Respiratory, thoracic and mediastinal disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Angioedema | Skin and subcutaneous tissue disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Aortic dissection | Vascular disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Deep vein thrombosis | Vascular disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Bundle branch block bilateral | Cardiac disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Coronary artery disease | Cardiac disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Nodal arrhythmia | Cardiac disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Diplopia | Eye disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Enteritis | Gastrointestinal disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Intestinal obstruction | Gastrointestinal disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Pancreatitis acute | Gastrointestinal disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Umbilical hernia | Gastrointestinal disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Drug withdrawal syndrome | General disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Non-cardiac chest pain | General disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Cholecystitis | Hepatobiliary disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Cholecystitis acute | Hepatobiliary disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Hepatic failure | Hepatobiliary disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Appendicitis | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Cystitis | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Lower respiratory tract infection | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Osteomyelitis | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Paronychia | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Peritonitis | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Postoperative abscess | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Respiratory tract infection viral | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Urosepsis | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Viral infection | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Bone contusion | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Concussion | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Craniocerebral injury | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Femoral neck fracture | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Head injury | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Humerus fracture | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Incisional hernia | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Joint dislocation | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Ligament sprain | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Post procedural haematoma | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Post procedural inflammation | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Radius fracture | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Rib fracture | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Road traffic accident | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Tendon injury | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Upper limb fracture | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Intervertebral disc compression | Musculoskeletal and connective tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Pathological fracture | Musculoskeletal and connective tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Spondylitis | Musculoskeletal and connective tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (23.1) | Systematic Assessment |
| |
| Benign breast neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (23.1) | Systematic Assessment |
| |
| Fibroadenoma of breast | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (23.1) | Systematic Assessment |
| |
| Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (23.1) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Lumbar radiculopathy | Nervous system disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Multiple sclerosis | Nervous system disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Multiple sclerosis relapse | Nervous system disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Myelopathy | Nervous system disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Quadriparesis | Nervous system disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Trigeminal neuralgia | Nervous system disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Major depression | Psychiatric disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Suicidal ideation | Psychiatric disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Suicide attempt | Psychiatric disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Urinary retention | Renal and urinary disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Benign prostatic hyperplasia | Reproductive system and breast disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Testicular infarction | Reproductive system and breast disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Uterine haemorrhage | Reproductive system and breast disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Uterine polyp | Reproductive system and breast disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Uterovaginal prolapse | Reproductive system and breast disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Pulmonary sarcoidosis | Respiratory, thoracic and mediastinal disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Angioedema | Skin and subcutaneous tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Lichen sclerosus | Skin and subcutaneous tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Aortic dissection | Vascular disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Deep vein thrombosis | Vascular disorders | MedDRA (23.1) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Injection site reaction | General disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA (22.0) | Systematic Assessment |
| |
| Injection related reaction | Injury, poisoning and procedural complications | MedDRA (22.0) | Systematic Assessment |
| |
| Blood immunoglobulin M decreased | Investigations | MedDRA (22.0) | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA (22.0) | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Injection site reaction | General disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA (23.1) | Systematic Assessment |
| |
| Injection related reaction | Injury, poisoning and procedural complications | MedDRA (23.1) | Systematic Assessment |
| |
| Blood immunoglobulin M decreased | Investigations | MedDRA (23.1) | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA (23.1) | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA (23.1) | Systematic Assessment |
|
This study was not powered for the analysis of some secondary endpoints as a stand-alone study. It was pre-specified in the study protocol to combine the data with study COMB157G2301 to address these endpoints.
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Novartis Pharmaceuticals | 862-778-8300 | Novartis.email@novartis.com |
| Prot_001.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Oct 17, 2019 | Sep 18, 2020 | SAP_000.pdf |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D012008 | Recurrence |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C527525 | teriflunomide |
Not provided
Not provided
Not provided
|
|
| Black or African American |
|
|
| White |
|
|
| Other |
|
|
| Unknown |
|
|
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
| Counts |
|---|
| Participants |
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
| Counts |
|---|
| Participants |
|
|
|
| Counts |
|---|
| Participants |
|
|
|
| Counts |
|---|
| Participants |
|
|
|
|
|
|
|
|
|
|
|
|
| Counts |
|---|
| Participants |
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Participants |
|
|
|
|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|
|
|
|
| Participants |
|
|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Baseline n=325 |
|
| ||||
| Week 4 n=346 |
|
| ||||
| Week 12 n=257 |
|
| ||||
| Week 24 n=243 |
|
| ||||
| Week 48 n=240 |
|
| ||||
| Week 96 n=304 |
|
|